Needham Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $27
Benzinga Newsdesk 2 days ago
Analyst RatingsNewsInitiationPrice Target
Needham analyst Gil Blum initiates coverage on Kazia Therapeutics (NASDAQ:KZIA) with a Buy rating and announces Price Target of $27.
Needham analyst Gil Blum initiates coverage on Kazia Therapeutics (NASDAQ:KZIA) with a Buy rating and announces Price Target of $27.